Neoadjuvant therapy for gastroesophageal adenocarcinoma

doi:10.5306/wjco.v7.i3.284

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 7, Issue 3

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8297)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-2) series.

Item

Count

PDF

838

WORD

275

HTML

3787

Tables (1-2)

540

Sum=5440

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

967

Download

1890

Sum=2857

Jun 10, 2016 (publication date) through Feb 23, 2026

Times Cited of This Article

Times Cited (10)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Minireviews

World J Clin Oncol. Jun 10, 2016; 7(3): 284-292
Published online Jun 10, 2016. doi: 10.5306/wjco.v7.i3.284

Neoadjuvant therapy for gastroesophageal adenocarcinoma

Emmanuelle Samalin, Marc Ychou

Emmanuelle Samalin, Marc Ychou, Digestive Oncology Department, Institut régional du Cancer de Montpellier (ICM), 34298 Montpellier, France

Author contributions: Both Samalin E and Ychou M designed the review and defined the plan and the issues discussed; Samalin E wrote the manuscript; Samalin E and Ychou M revised the manuscript and approved the final version.

Conflict-of-interest statement: Emmanuelle Samalin has received fees for serving as consultant for Roche and Lilly laboratories. Marc Ychou has received fees for serving as consultant for Roche, Lilly and Bayer laboratories.

Correspondence to: Emmanuelle Samalin, MD, Digestive Oncology Department, Institut régional du Cancer de Montpellier (ICM), 208 avenue des Apothicaires, 34298 Montpellier, France. emmanuelle.samalin@icm.unicancer.fr

Telephone: +33-4-67613136 Fax: +33-4-67613022

Received: July 29, 2015
Peer-review started: July 31, 2015
First decision: September 28, 2015
Revised: March 24, 2016
Accepted: April 7, 2016
Article in press: April 11, 2016
Published online: June 10, 2016
Processing time: 309 Days and 12.5 Hours

Core Tip

Core tip: Gastric and esophageal adenocarcinomas are one of the main causes of cancer-related death worldwide. The incidence of gastroesophageal junction adenocarcinoma is rapidly rising in Western countries. Surgical resection is currently the major curative treatment. As the 5-year survival rate highly depends on the pTNM stage, the treatment strategy is very challenging for oncologists. Several treatments, including systemic chemotherapy, are being assessed to prevent recurrences and improve overall survival. New strategies, such as induction chemotherapy followed by preoperative chemoradiotherapy, targeted therapies and new cytotoxic regimens in perioperative chemotherapy, are currently assessed to improve current standards and develop more tailored therapeutic interventions.